SmithKline topical loperamide
Executive Summary
Licensing agreement signed with Adolor for worldwide (excluding Korea) prescription and OTC development and commercial rights to topical dermal loperamide product ADL 2-1294 for use in the treatment of inflammatory pain, itching and other undisclosed indications. Adolor will receive an up-front payment and up to $48 mil. from development milestone payments. ADL 2-1294 lacks the CNS side effects associated with other narcotic opioids because it does not cross the blood-brain barrier, Adolor says, making it the only opioid drug that is not in a DEA controlled-drug schedule